How effective is Alpelisib?

Alpelisib (Alpelisib) is mainly used in the treatment of breast cancer, especially for patients with PIK3CA gene mutations. The following will briefly discuss the effect of Apelvis in the treatment of breast cancer based on the results of some key clinical trials.

Apelix, as a PI3K inhibitor, targets the specificity of PIK3CA gene mutations in breast cancer by inhibiting the abnormal activation of the PI3K signaling pathway, thus affecting the proliferation and survival of tumor cells. Here are some of the key clinical trials on Apelvis:

SOLAR-1Test:

The SOLAR-1 trial is an important clinical trial of apelvis, which is mainly studying the drug's effect in the treatment of breast cancer. The trial is targeting patients with HR-positive, HER2-negative breast cancer and PIK3CA mutations. The trial results showed that patients who received apelvis had improved progression-free survival (PFS), an important efficacy measure, compared with steroids plus apelvis or placebo. PFSProlongation means that apelvis has a significant therapeutic effect in this patient population.

NEO-ORB（NEOadjuvant study of the PI3K inhibitor BKM120 or placebo during neoadjuvant chemotherapy and HER2-negative hormonal receptor-positive (HR+) breast cancer) trial:

The NEO-ORBtrial was designed to evaluate the effect of BKM120 (i.e., apelvis) or placebo during neoadjuvant chemotherapy and also focused on hormone receptor-positive, HER2negative breast cancer. Although the trial's primary endpoint was change in pathological response after neoadjuvant treatment, the results may provide clues about the potential effectiveness of apelvis in the treatment of early-stage breast cancer.

BYLieve（A Phase II, Multicenter, Open-label, Two-arm, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients with PIK3CA Mutant, Hormone Receptor Positive, HER2-negative Advanced Breast Cancer) trial:

The BYLieve trial is designed to evaluate the efficacy and safety of apelvis with suliviti fumarate or letrozole in the treatment of PIK3CAmutated hormone receptor-positive, HER2-negative advanced breast cancer. This is a non-comparative study, and its primary endpoints include overall response rate (ORR) and duration of sustained response, which are critical to understanding the efficacy of apelvis in this patient population.

Overall, apelvis, as a drug targeting thePI3K signaling pathway, has achieved some positive clinical trial results in the treatment of breast cancer. However, patients and physicians should note when considering the use of Apelvis that its indications are currently limited to HR-positive, HER2-negative breast cancer and require patients with PIK3CA gene mutations. In addition, like any drug, Apelix may also cause some side effects, including but not limited to high blood sugar, skin reactions, etc., so patients need to understand it carefully before use and use it under the supervision of a professional doctor.

It is important to note that the results of clinical trials are part of scientific research, and knowledge in the medical field is constantly evolving. Therefore, it is recommended that patients have in-depth discussions with their doctors when formulating a treatment plan to fully understand the patient's own situation and the latest research and treatment options.

Apelis has not yet been launched in China, so it is not included in medical insurance. Therefore, patients cannot purchase it domestically and need to purchase Apelis through overseas channels. In foreign countries, the original Apelvis drug is mainly used. There are European and Indian versions of the original drug on the market. The price of the European version of the original drug is as high as tens of thousands of yuan. Relatively speaking, the price of the Indian version of the original drug is around four to five thousand yuan. The price is still relatively cheap. Moreover, the ingredients and efficacy of the European and Indian original drugs are consistent.